Bristol/Gilead HIV Combo Therapy Will Go To FDA By Mid-Year
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb and Gilead plan to submit an NDA in the second quarter for a fixed-dose combination of Bristol’s Sustiva (efavirenz) and Gilead’s Truvada (emtricitabine/tenofovir disoproxil).